111536
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
多发性骨髓瘤患者血清中 BCL2 相互作用蛋白 3 样（BNIP3L）的表达及其临床意义
Authors Nong Y , Xiong Z, Wang Q , Gu M, Zheng Y, Wang Y , Wu J, Huang C, Li Z, Luo J, Ling Z , Li R
Received 30 July 2025
Accepted for publication 6 December 2025
Published 17 December 2025 Volume 2025:15 Pages 247—264
DOI https://doi.org/10.2147/BLCTT.S557238
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Wilson Gonsalves
Yanyu Nong,1,* Zengyi Xiong,1,* Qicai Wang,1,* Mengyuan Gu,1 Yanting Zheng,1 Yifan Wang,1 Jing Wu,2 Chunni Huang,1 Zhongqing Li,3 Jun Luo,3 Zhian Ling,4 Ruolin Li2
1Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Nanning, Guangxi, People’s Republic of China; 2Department of Scientific Research, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China; 3Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China; 4Department of Emergency, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Ruolin Li, Department of Scientific Research, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China, Email ruolin8297@163.com Zhian Ling, Department of Emergency, Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China, Email zhianling@163.com
Background: BNIP3L regulates mitophagy and apoptosis, and its dysregulation is closely linked to the development and progression of cancers. Studies have shown that BNIP3L is valuable for assessing tumor progression and prognosis. This study aims to investigate the diagnostic and prognostic significance of serum BNIP3L levels in multiple myeloma (MM).
Methods: The serum level of BNIP3L were measured in 152 MM patients and 158 healthy controls by Enzyme-Linked Immunosorbent Assay (ELISA). Receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic ability of MM. The prognostic relevance of serum BNIP3L levels in MM patients was assessed using Kaplan-Meier survival analysis and Cox regression.
Results: Serum BNIP3L levels were significantly elevated in MM patients compared to healthy controls (P < 0.001) and demonstrated significant diagnostic value (Area Under the Curve (AUC) = 0.744). Higher BNIP3L levels correlated negatively with serum calcium (P = 0.02) and M protein (P = 0.03). MM patients with extramedullary infiltration (EMI) or high-risk cytogenetic abnormalities had higher serum BNIP3L levels compared to those without these features (all P < 0.05). BNIP3L levels were significantly higher in non-transplant patients compared to autologous stem cell transplant (ASCT) patients (P = 0.01). And patients achieving Very Good Partial Response (VGPR) efficacy had significantly lower serum BNIP3L levels than those who achieving only Partial Response (PR) (P = 0.04). Compared to patients with low serum BNIP3L levels, those with high levels exhibited a trend toward poorer overall survival (Hazard Ratio (HR) = 1.40, 95%Confidence Interval (CI): 0.47– 4.19).
Conclusion: This study identified serum BNIP3L as a potential diagnostic biomarker for active MM. Elevated BNIP3L levels were significantly associated with adverse clinical characteristics, suboptimal treatment response, and a trend toward inferior survival. Consequently, measuring serum BNIP3L could be valuable for monitoring disease progression and prognostic evaluation in MM patients.
Keywords: BNIP3L, multiple myeloma, serum biomarker, diagnosis, prognosis
1Department of Clinical Laboratory, The First Affiliated Hospital of Guangxi Medical University, Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Nanning, Guangxi, People’s Republic of China; 2Department of Scientific Research, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China; 3Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China; 4Department of Emergency, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Ruolin Li, Department of Scientific Research, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China, Email ruolin8297@163.com Zhian Ling, Department of Emergency, Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China, Email zhianling@163.com
Background: BNIP3L regulates mitophagy and apoptosis, and its dysregulation is closely linked to the development and progression of cancers. Studies have shown that BNIP3L is valuable for assessing tumor progression and prognosis. This study aims to investigate the diagnostic and prognostic significance of serum BNIP3L levels in multiple myeloma (MM).
Methods: The serum level of BNIP3L were measured in 152 MM patients and 158 healthy controls by Enzyme-Linked Immunosorbent Assay (ELISA). Receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic ability of MM. The prognostic relevance of serum BNIP3L levels in MM patients was assessed using Kaplan-Meier survival analysis and Cox regression.
Results: Serum BNIP3L levels were significantly elevated in MM patients compared to healthy controls (P < 0.001) and demonstrated significant diagnostic value (Area Under the Curve (AUC) = 0.744). Higher BNIP3L levels correlated negatively with serum calcium (P = 0.02) and M protein (P = 0.03). MM patients with extramedullary infiltration (EMI) or high-risk cytogenetic abnormalities had higher serum BNIP3L levels compared to those without these features (all P < 0.05). BNIP3L levels were significantly higher in non-transplant patients compared to autologous stem cell transplant (ASCT) patients (P = 0.01). And patients achieving Very Good Partial Response (VGPR) efficacy had significantly lower serum BNIP3L levels than those who achieving only Partial Response (PR) (P = 0.04). Compared to patients with low serum BNIP3L levels, those with high levels exhibited a trend toward poorer overall survival (Hazard Ratio (HR) = 1.40, 95%Confidence Interval (CI): 0.47– 4.19).
Conclusion: This study identified serum BNIP3L as a potential diagnostic biomarker for active MM. Elevated BNIP3L levels were significantly associated with adverse clinical characteristics, suboptimal treatment response, and a trend toward inferior survival. Consequently, measuring serum BNIP3L could be valuable for monitoring disease progression and prognostic evaluation in MM patients.
Keywords: BNIP3L, multiple myeloma, serum biomarker, diagnosis, prognosis